Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFN-Kinoid in Adult Subjects With Dermatomyositis
NCT02980198Phase 2Withdrawn
- Sponsor
- Neovacs
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, single-blind trial in dermatomyositis (DM) comparing IFN-Kinoid with Placebo (2 arms). Primary endpoint: Change from baseline in the expression of IFN-induced genes at Week 48. Planned start May 2017; status: withdrawn.
02
Drugs
IFN-K
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02980198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980198.